Biotech 2050 Podcast
Psychedelics, Longevity, and Wellbeing, Christian Angermayer, Founder, Apeiron Investment Group
8 months ago
Adapting Through Disruption in Biotech, David Esposito, President & CEO, ONL Therapeutics
9 months ago
Overcoming Capital Challenges in Biotech, Jak Knowles, President & CEO, Affini-T Therapeutics
10 months ago
A novel approach to advancing breast cancer therapy, Sean Bohen, President & CEO, Olema Oncology
10 months ago
Next-gen gene editing, Keith Gottesdiener, President & CEO, Jeremy Duffield, CSO, Prime Medicine
11 months ago